What's happened
The US is ending its global health supply program, risking shortages of HIV and malaria medicines in Africa and Haiti. The transition to new procurement methods is uncertain, with potential gaps in life-saving supplies amid ongoing aid reductions and policy shifts.
What's behind the headline?
The US's decision to end its longstanding supply chain program reflects a broader shift in foreign aid policy, emphasizing bilateral agreements and private logistics. While intended to reduce inefficiencies, this transition risks destabilizing the supply of critical health commodities. Short-term disruptions have already occurred, including shortages of malaria drugs and HIV prevention tools, which threaten to reverse progress made over decades. The move towards reliance on the Global Fund and local production, such as in South Africa, offers a sustainable path, but the timeline—potentially extending to 2027—may be too optimistic given the complexities of procurement and distribution in remote regions. The US's focus on cost-cutting and efficiency must be balanced against the urgent need to maintain uninterrupted access to life-saving medicines, especially for vulnerable populations in Africa and Haiti. Failure to manage this transition effectively could lead to increased HIV infections and malaria-related deaths, undermining global health gains.
How we got here
Since 2016, the US managed its HIV and malaria donations through the Chemonics-led Global Health Supply Chain Program, delivering over $5 billion to 90 countries. The program was halted after President Trump froze aid in January 2025, leading to disruptions. The US is now shifting towards bilateral agreements and exploring partnerships with the Global Fund, but these changes risk creating shortages and gaps in essential medicines, especially in hard-to-reach areas.
Our analysis
Reuters reports that the US is ending its aid program with Chemonics, raising concerns about supply gaps and disruptions in HIV and malaria medicines across Africa and Haiti. The article highlights the US's shift towards bilateral health pacts and private logistics, but warns that the transition timeline—originally set for September 2026 and now possibly extending to November 2027—may be unrealistic, risking shortages. All Africa emphasizes the ongoing disruptions caused by aid cuts, including reduced HIV testing and prevention services, and highlights the efforts of volunteers in Nigeria who have helped bridge gaps in treatment. The Independent underscores the broader impact of aid reductions on HIV prevention, especially for women and girls in sub-Saharan Africa, and criticizes the UK’s aid cuts for exacerbating these issues. Both sources illustrate the critical importance of sustained funding and local production to ensure continued access to essential medicines and prevent setbacks in global health progress.
More on these topics
-
Uganda - Country in East Africa
Uganda, officially the Republic of Uganda, is a landlocked country in East-Central Africa. It is bordered to the east by Kenya, to the north by South Sudan, to the west by the Democratic Republic of the Congo, to the south-west by Rwanda, and to the south